Image via BioCentury
Last updated
Incyte: Ma Activity
Incyte acquiring Vega Therapeutics (Star Therapeutics' subsidiary) for $1.25B upfront plus up to $750M in milestone payments. Vega has Phase 3 bleeding disorder candidate.
Source: BioCentury
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in the sector.
Market context: Backdrop: a 107.2 (Hot) Talent Market Index (down 1.8 on the month) with EMEA activity easing (-6.4pts).
Incyte: 2 signals in the last 90 days; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 28 days.
Also at Incyte →
More signals across EMEA
Ma Activity · EMEA
Tate & Lyle →Tate & Lyle accepted a £2.7bn takeover offer from US rival Ingredion in June 2026, following a 10% profit decline to £238m amid slowing consumer demand.
Ma Activity · EMEA
Mitie →Mitie agreed to a £3.1bn takeover by private-equity owned OCS Group at 221.6p per share, representing a 44.7% premium to prior close. Transaction subject to shareholder approval.
Ma Activity · EMEA
Volue →Volue acquires FlexPowerHub, a power trading platform, to expand capabilities in energy market infrastructure and trading.
Ma Activity · EMEA
Adzuna →Adzuna has acquired Joblift, consolidating job search and recruitment technology platforms.
Ma Activity · EMEA
Temenos →Temenos completed acquisition of Swiss fintech additiv, integrating AI-powered wealth management orchestration tools into core banking platform
Ma Activity · EMEA
Jacobs →Jacobs won three U.K. National Highways contracts, indicating successful bid activity and contract acquisition in the UK infrastructure market.
Intelligence powered by Autonodal ↗